Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Brand, Ronald ^a   Putter, Hein ^a   van Biezen, Anja ^a   Niederwieser, Dietger ^b   Martino, Rodrigo ^c   Mufti, Ghulam ^d   Onida, Francesco ^e   Symeonidis, Argiris ^f   Schmid, Christoph ^g   Garderet, Laurent ^h   Robin, Marie ⁱ   van Gelder, Michel ^j   Finke, Jürgen ^k   Bornhäuser, Martin ^l   Kobbe, Guido ^m   Germing, Ulrich ^m   de Witte, Theo ⁿ   Kröger, Nicolaus ^o  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f Department of Hematology   (Greece)

^g Hopital St Louis ^*  (Germany)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j MAASTRICHT UNIVERSITY   (Netherlands)

^k UNIVERSITY OF FREIBURG   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^m UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DEATH; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT SELECTION; REGISTER; SURVIVAL RATE; SURVIVOR;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84885032132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074368     Document Type: Article

References (17)

1. De Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, et al. (2000) Hematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukemia Working Party of the EBMT. Br J Haematol 110: 620-630. doi:10.1046/j.1365-2141.2000.02200.x. PubMed: 10997974.
2. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, et al. (2002) Conditioning with targeted busulfan and cyclphosphamide for hemopoieticstem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100: 1201-1207. doi:10.1182/blood-2002-02-0527. PubMed: 12149198.
3. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, et al. (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100: 1997-2004. PubMed: 12200358.
4. Cutler AS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579-585. doi:10.1182/blood-2004-01-0338. PubMed: 15039286.
5. Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, et al. (2006) Reduced-toxicity conditioning with treosulfan, fludarbine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37: 339-344. doi:10.1038/sj.bmt.1705259. PubMed: 16415898.
6. Ay Ho, Pagliuca A, Kenyon M, Parker JE, Mijovic A, et al. (2004) Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzimab (FBC) conditioning. Blood 104: 1616-1623. doi:10.1182/blood-2003-12-4207. PubMed: 15059843.
7. Lim Y, Brand R, Martino R, van Biezen A, Finke J, et al. (2010) Allogeneic hematopoietic stem cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukaemia. J Clin Oncol 28: 405-411. doi:10.1200/JCO.2009.21.8073. PubMed: 20008642.
8. Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, et al. (2005) Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 19: 7-12. PubMed: 15526016.
9. Martino R, Caballero MD, Pérez-Simón JA, Canals C, Solano C, et al. (2002) Evidence for graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100: 2243-2245. doi:10.1182/blood-2002-02-0400. PubMed: 12200391.
10. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, et al. (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14: 246-255. doi:10.1016/j.bbmt.2007.11.012. PubMed: 18215785.
11. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, et al. (2006) Myelodysplastic Syndrome Subcommittee of the Chronic Leukemia Working Party of the EBMT. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108: 836-846. doi:10.1182/blood-2005-11-4503. PubMed: 16597592.
12. Putter H, Fiocco M, Geskus RB, (2007) Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26: 2389-2430. doi:10.1002/sim.2712. PubMed: 17031868.
13. de Wreede LC, Fiocco M, Putter H, (2010) The m-state package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 99: 261-274. doi:10.1016/j.cmpb.2010.01.001. PubMed: 20227129.
14. Gill RD, Keiding N, (1990) Random truncation models and Markov processes. Ann Statist 18: 582-602. doi:10.1214/aos/1176347617.
15. Grambsch P, Therneau T, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526. doi:10.1093/biomet/81.3.515.
16. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, et al. (2007) High-resolution donor recipient HLA-matching contributes to the success of unrelated donor marrow transplantation. Blood 110: 4576-4583. doi:10.1182/blood-2007-06-097386. PubMed: 17785583.
17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, et al. (2009) International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232. doi:10.1016/S1470-2045(09)70003-8. PubMed: 19230772.